ICML 2025 | Phase III study of tabelecleucel for patients with EBV+ PTLD: updated results
Sylvain Choquet, MD, APHP, Paris, France, briefly discusses updated results from a study investigating the safety and efficacy of tabelecleucel for patients with relapsed/refractory (R/R) Epstein-Barr virus-associated post-transplant lymphoproliferative disorders (EBV+ PTLD). This interview took place during the 18th International Conference on Malignant Lymphoma (18-ICML) in Lugano, Switzerland.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
So the results, it is an ongoing study and the results have already been published in 2024 on 43 patients so we make an updated data on 75 patients and so we confirm that half of patients will respond, will be more CR than partial response in these patients and even if the patient is in partial response, the response is the same with CR, with a plateau and usually patients do not relapse. The PFS at one year is more than 70% and the overall survival for the whole cohort is around 55% and for responders 80%...
So the results, it is an ongoing study and the results have already been published in 2024 on 43 patients so we make an updated data on 75 patients and so we confirm that half of patients will respond, will be more CR than partial response in these patients and even if the patient is in partial response, the response is the same with CR, with a plateau and usually patients do not relapse. The PFS at one year is more than 70% and the overall survival for the whole cohort is around 55% and for responders 80%. So really it changed totally the way to treat relapsed refractory EBV+ PTLD and we have authorization to use it in Europe.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
